Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
France Targets Shein, Temu With Fast-Fashion Fees 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
OpenAI Rejects Apple Trade Secret Theft Claims 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Add as a preferred source on Google
MENLO PARK, Calif., March 08, 2018 -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today announced that company management will present an overview of the company at the Cowen & Company 38th Annual Healthcare Conference.
- Location: Boston, MA
- Presentation date: Wednesday, March 14, 2018
- Presentation time: 10:40 a.m. ET
A live audio webcast and archive of the presentation will be available at http://investor.dermira.com.
About Dermira
Dermira is a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions. Dermira is committed to understanding the needs of both patients and physicians and using its insight to identify and develop leading-edge medical dermatology programs. Dermira’s pipeline includes two late-stage product candidates that could have a profound impact on the lives of patients: glycopyrronium tosylate (formerly DRM04), for which a New Drug Application is under review by the U.S. Food and Drug Administration for the treatment of primary axillary hyperhidrosis (excessive underarm sweating beyond what is needed for normal body temperature regulation), and lebrikizumab, in Phase 2b development for the treatment of moderate-to-severe atopic dermatitis. Dermira is headquartered in Menlo Park, Calif. For more information, please visit http://www.dermira.com. Follow @DermiraInc on Twitter and LinkedIn.
In addition to filings with the Securities and Exchange Commission (SEC), press releases, public conference calls and webcasts, Dermira uses its website (www.dermira.com), LinkedIn page (https://www.linkedin.com/company/dermira-inc) and corporate Twitter account (@DermiraInc) as channels of distribution of information about its company, product candidates, planned financial and other announcements, attendance at upcoming investor and industry conferences and other matters. Such information may be deemed material information and Dermira may use these channels to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Dermira’s website, LinkedIn page and Twitter account in addition to following its SEC filings, press releases, public conference calls and webcasts.
Contacts:
Media:
Erica Jefferson
Vice President, Corporate Communications
650-421-7216
[email protected]
Investors:
Ian Clements, Ph.D.
Vice President, Investor Relations
650-422-7753
[email protected]
Robert H. Uhl
Westwicke Partners
Managing Director
858-356-5932
[email protected]
